Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$445K Buy
3,461
+858
+33% +$100K 0.1% 80
2026
Q1
$313K Buy
2,603
+270
+12% +$31.2K 0.08% 95
2025
Q4
$246K Buy
+2,333
New +$219K 0.07% 117
2025
Q3
Sell
-2,567
Closed -$206K 125
2025
Q2
$206K Sell
2,567
-417
-14% -$33.1K 0.07% 107
2025
Q1
$268K Sell
2,984
-297
-9% -$27.7K 0.19% 58
2024
Q4
$326K Sell
3,281
-248
-7% -$25.6K 0.21% 55
2024
Q3
$401K Buy
3,529
+522
+17% +$62K 0.28% 47
2024
Q2
$372K Buy
3,007
+543
+22% +$69.9K 0.29% 40
2024
Q1
$327K Buy
2,464
+98
+4% +$12.1K 0.26% 45
2023
Q4
$299K Buy
2,366
+279
+13% +$29K 0.22% 46
2023
Q3
$216K Buy
+2,087
New +$225K 0.13% 58
2022
Q4
Sell
-345
Closed -$30K 259
2022
Q3
$30K Buy
+345
New +$30.8K 0.02% 130

Other funds holding MRK

EdgeRock Capital's MRK Position: Q2 2026 in Review

EdgeRock Capital increased its Merck (MRK) stake by 33% in Q2 2026, buying an estimated $100K and bringing the position to 3,461 shares worth $445K. The position accounts for 0.1% of the portfolio, ranked #80.

EdgeRock Capital first reported a position in MRK in Q3 2022 and has held it in 12 quarters since. 3,833 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • EdgeRock Capital held 3,461 shares of Merck worth $445K as of Q2 2026.
  • EdgeRock Capital bought 858 Merck shares in Q2 2026, an estimated $100K.
  • Merck made up 0.1% of EdgeRock Capital's portfolio in Q2 2026, its #80 holding.
  • EdgeRock Capital first reported a position in Merck in Q3 2022 and has held it in 12 quarters since.
  • 3,833 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on EdgeRock Capital's 13F filing for Q2 2026, filed 24 Jul 2026.